Vyome Holdings, Inc. (HIND)

US — Healthcare Sector
Peers: CCCC  ARMP  SGMO  TNXP  CGEN  NVCT  IPHA  IMDX  CDXS  OABI 

Automate Your Wheel Strategy on HIND

With Tiblio's Option Bot, you can configure your own wheel strategy including HIND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HIND
  • Rev/Share 31.5341
  • Book/Share 29.458
  • PB 0.2424
  • Debt/Equity 0.0153
  • CurrentRatio 1.9358
  • ROIC -3.6922

 

  • MktCap 121557158.0
  • FreeCF/Share -22.2349
  • PFCF -41.0992
  • PE -0.0533
  • Debt/Assets 0.0055
  • DivYield 0
  • ROE -4.9326

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
HIND
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings Third Quarter 2025 Earnings Release.

Read More
image for news Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
HIND
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1). Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States.

Read More
image for news Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

About Vyome Holdings, Inc. (HIND)

  • IPO Date 2016-10-06
  • Website https://www.vyometx.com
  • Industry Biotechnology
  • CEO Venkateswarlu Nelabhotla
  • Employees 18
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.